Clin Orthop Surg.  2014 Dec;6(4):439-442. 10.4055/cios.2014.6.4.439.

The Analysis of Treatment of Aggressive Fibromatosis Using Oral Methotrexate Chemotherapy

• Yoon GW
• Kim JD
• Chung SH

• KMID: 1794733
• DOI: http://doi.org/10.4055/cios.2014.6.4.439

Abstract

BACKGROUND
Aggressive fibromatosis is a rare but invasive tumor infiltrating widely between fascia and muscle fibers. It has a high tendency to be locally recurrent despite complete resection. Effectiveness of adjuvant treatment for aggressive fibromatosis including radiotherapy, pharmacological agents, hormonal treatments, and chemotherapy have been previously reported. The purpose of this article was to collect and analyze all information regarding the effectiveness and side effects of oral methotrexate in aggressive fibromatosis.
METHODS
From 2005 to 2011, eleven patients with aggressive fibromatosis treated with oral methotrexate at our institution were analyzed in this study. Oral methotrexate was administered once per week at 10 mg per week. Authors collected information about effectiveness concerning cases of local recurrence and metastasis.
RESULTS
Eleven patients had remission, two patients had local recurrence. Fatal complications or toxicity were not observed.
CONCLUSIONS
Oral methotrexate given at this dose and schedule was considered as a useful treatment in primary inoperable fibromatosis and recurrent fibromatosis.

Keyword

Aggressive fibromatosis; Oral methotrexate

MeSH Terms

Administration, Oral
Adolescent
Adult
Aged
Antimetabolites, Antineoplastic/*administration & dosage
Child
Female
Fibromatosis, Aggressive/*drug therapy/surgery
Humans
Male
Methotrexate/*administration & dosage
Middle Aged
Neoplasm Recurrence, Local/*drug therapy/surgery
Retrospective Studies
Young Adult
Antimetabolites, Antineoplastic
Methotrexate

Reference

1. Biermann JS. Desmoid tumors. Curr Treat Options Oncol. 2000; 1(3):262–266.

2. Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982; 77(6):665–673.

3. Mendez-Fernandez MA, Gard DA. The desmoid tumor: "benign" neoplasm, not a benign disease. Plast Reconstr Surg. 1991; 87(5):956–960.

4. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer. 1989; 64(6):1192–1194.

5. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors: summary of 19 cases and review of the literature. Ann Surg. 1989; 210(6):765–769.

6. Hunt RT, Morgan HC, Ackerman LV. Principles in the management of extra-abdominal desmoids. Cancer. 1960; 13(4):825–836.

7. Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer. 1993; 72(5):1637–1641.

8. Khorsand J, Karakousis CP. Desmoid tumors and their management. Am J Surg. 1985; 149(2):215–218.

9. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986; 151(2):230–237.

10. Reitamo JJ. The desmoid tumor. IV. Choice of treatment, results, and complications. Arch Surg. 1983; 118(11):1318–1322.

11. Mehrotra AK, Sheikh S, Aaron AD, Montgomery E, Goldblum JR. Fibromatoses of the extremities: clinicopathologic study of 36 cases. J Surg Oncol. 2000; 74(4):291–296.

12. Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000; 88(7):1517–1523.

13. Enzinger FM, Shiraki M. Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid): analysis of thirty cases followed up for ten or more years. Cancer. 1967; 20(7):1131–1140.

14. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004; 100(3):612–620.

15. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998; 42(5):1007–1014.

16. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer. 2003; 97(4):1134–1135.

17. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Advanced aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol. 2011; 50(3):455–461.

18. Weiss A, Lackman R. Therapy of desmoid tumors, fibromatosis, and related neoplasms. Int J Oncol. 1995; 7(4):773–776.

19. van der Hul RL, Seynaeve C, van Geel BN, Verweij J. Low Dose methotrexate and vinblastine, given weekly to patients With desmoid tumours, is associated with major toxicity. Sarcoma. 2003; 7(3-4):153–157.